Play Earnings CallPlay Earnings Call
Corvus Pharmaceuticals, Inc. (CRVS) Discusses Phase 1 Clinical Trial Results of Soquelitinib in Atopic Dermatitis with Focus on Cohort 4 January 20, 2026 8:00 AM EST
Company Participants
Richard Miller – Co-Founder, President, CEO & Chairman of the Board
Leiv Lea – Chief Financial Officer
Conference Call Participants
Zack Kubow – Real Chemistry, Inc.
Jiale Song – Jefferies LLC, Research Division
Aydin Huseynov – Ladenburg Thalmann & Co. Inc., Research Division
Li Wang Watsek – Cantor Fitzgerald & Co., Research Division
Graig Suvannavejh – Mizuho Securities USA LLC, Research Division
Etzer Darout – Barclays Bank PLC, Research Division
Jeffrey Jones – Oppenheimer & Co. Inc., Research Division
Xun Lee – H.C. Wainwright & Co, LLC, Research Division
Presentation
Operator
Good morning, everyone. Thank you for standing by, and welcome to the Corvus Pharmaceuticals Conference Call. [Operator Instructions] It is now my pleasure to turn the call over to Zack Kubow of Real Chemistry. Please go ahead, sir.
Zack Kubow
Real Chemistry, Inc.
Thank you, operator, and good morning, everyone. Thanks for joining us today on the call. This conference call is being webcast with presentation slides. We encourage participants to join the webcast in order to view the slides. You can find the link to join the webcast on the Investor Relations homepage of the Corvus website. On the call today are Dr. Richard Miller, Chief Executive Officer; Leiv Lea, Chief Financial Officer; Jeff Arcara, Chief Business Officer; Dr. Ben Jones, Senior Vice President, Pharmaceutical Development; and Dr. Suresh Mahabhashyam, Vice President, Clinical Development.
The executive team will open the call with some prepared remarks, followed by a question-and-answer period. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Forward-looking statements are based on estimates and assumptions as of today and are subject to risks and uncertainties that
